Antigen News and Research

RSS

Avacta's SARS-COV-2 neutralizing Affimer reagents show therapeutic potential for COVID-19

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that several of the Affimer reagents recently generated for development of a point-of-care COVID-19 antigen saliva test have now also been shown to block the interaction between the virus’ spike protein and ACE2, a receptor on human cells that is key to the virus infection pathway.

From Avacta Life Sciences Ltd. 18 May 2020

Study shows human monoclonal antibodies can effectively neutralize SARS-CoV-2

US researchers have published a proof of concept on the efficacy of human monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in laboratory conditions, as well as their pioneering use in a mouse model. The study is available on the preprint server bioRxiv*.

17 May 2020

Developing a COVID-19 antigen test

News-Medical speaks to Alastair Smith, the CEO of Avacta, about the process behind their newly developed antigen test for COVID-19.

From Avacta Life Sciences Ltd. 15 May 2020

Biologic drug can help treat contact dermatitis

APOSEC it is a biologic wound-healing agent developed by thoracic surgeon Hendrik Jan Ankersmit from MedUni Vienna.

15 May 2020

More cancer patients could benefit from CAR T-cell therapy, Moffitt study suggests

Chimeric antigen receptor T-cell therapy, or CAR T, has become a game changer for lymphoma and leukemia patients who have relapsed or become resistant to previous treatments.

14 May 2020

New discovery may contribute to early identification of aggressive breast tumors

Immune system cells in the blood of breast cancer patients undergo alterations early in the disease course, according to a study published in the journal Clinical & Translational Immunology.

12 May 2020

Study provides genetic explanation behind the sex bias observed in certain diseases

Some diseases exhibit a clear sex bias, occurring more often, hitting harder or eliciting different symptoms in men or women.

12 May 2020

Study shows COVID-19 vulnerability is highly dependent on host genetic architecture

A new US study available on the preprint server medRxiv reveals certain genetic variations that are associated with infection susceptibility and diverse clinical presentation of coronavirus disease (COVID-19) – including asymptomatic cases and severe forms of the disease in younger patients.

10 May 2020

Researchers discover new type of antigen-presenting immune cell

With a discovery that could rewrite the immunology textbooks, an international group of scientists, including the teams of Bart Lambrecht, Martin Guilliams, Hamida Hammad, and Charlotte Scott (all from the VIB-UGent Center for Inflammation Research) identified a new type of antigen-presenting immune cell.

8 May 2020

Predicting the dose for repurposing nitazoxanide in COVID-19

A new study published on the preprint server medRxiv in May 2020 reports a model that could help evolve appropriate dosage protocols for future clinical trials of the repurposed drug nitazoxanide in COVID-19 prevention and treatment. The researchers say, “It was possible to achieve plasma and lung tizoxanide concentrations, using proven safe doses of nitazoxanide, that exceed the EC90 for SARS-CoV-2.”

7 May 2020

People thinking they have had COVID-19 could increase transmission

A study conducted by researchers in the UK has found that people who think they have had COVID-19 are more likely to believe they are immune to the infection and less likely to follow social distancing rules.

6 May 2020

OXGENE™ reports third consecutive year of 100% year on year revenue growth

OXGENE™ has more than doubled its annual revenue in the financial year just closed, in the third consecutive year of 100% year on year revenue growth.

From OXGENE 6 May 2020

Loss of smell may be related to neuroinvasive propensity of SARS-CoV-2

The novel coronavirus has rapidly infected millions over the world in over 187 countries and territories, causing hundreds of thousands of deaths. One of the often-neglected and under-reported symptoms of the virus is the loss of the sense of smell or anosmia. Now, a new study out of Germany published on the preprint server medRxiv in April 2020 provides a quantified estimate of the magnitude of anosmia as a symptom of the coronavirus.

4 May 2020

Uncovering immune cell reactions in COVID-19

A new study published on the preprint server medRxiv in April 2020 suggests that an overactive immune response is responsible for the more severe manifestations of the illness.

4 May 2020

New information on viral antigens could improve COVID-19 testing

Researchers in France and China have characterized antibody responses to a wide range of antigens present on severe acute respiratory syndrome-related coronavirus (SARS-CoV-2) among patients with coronavirus disease 2019 (COVID-19).

4 May 2020

Avacta Group plc forms COVID-19 antigen diagnostic collaboration with Adeptrix

Avacta Group plc is pleased to announce that it has entered into a collaboration with Adeptrix to develop a high throughput COVID-19 antigen test.

From Avacta Life Sciences Ltd. 1 May 2020

ProteoGenix launches first Human Immune COVID-19 antibody library

ProteoGenix, a global leader in antibody production, is pleased to announce the first Human Immune COVID-19 library for the fast discovery of potent antibodies against SARS-CoV-2.

30 Apr 2020

GlobalData: Mass home testing for Covid-19 isn’t without its risks

Unfettered access to rapid and safe Covid-19 tests will be one of the most critical factors in reducing the spread of the disease.

29 Apr 2020

C-Path receives EMA’s letter of support to facilitate the diagnoses of type 1 diabetes

The Critical Path Institute (C-Path) today announced that its Type 1 Diabetes (T1D) Consortium has received a letter of support from the European Medicines Agency (EMA) to facilitate the development and validation of the proposed regulatory qualification of pancreatic islet autoantibodies commonly used in clinical practice to diagnose T1D: insulin autoantibodies, glutamic acid decarboxylase 65, and insulinoma antigen-2 autoantibodies as enrichment biomarkers for T1D clinical trials.

29 Apr 2020

Researchers receive ERC grant to speed up the diagnosis of autoimmune encephalitis

Autoimmune encephalitis (AE) is a disease that affects 2-3 people out of 100,000, in which our immune system attacks our own brain causing neurological and psychiatric symptoms.

28 Apr 2020

Antigen News and Research

Avacta's SARS-COV-2 neutralizing Affimer reagents show therapeutic potential for COVID-19

Study shows human monoclonal antibodies can effectively neutralize SARS-CoV-2

Developing a COVID-19 antigen test

Biologic drug can help treat contact dermatitis

More cancer patients could benefit from CAR T-cell therapy, Moffitt study suggests

New discovery may contribute to early identification of aggressive breast tumors

Study provides genetic explanation behind the sex bias observed in certain diseases

Study shows COVID-19 vulnerability is highly dependent on host genetic architecture

Researchers discover new type of antigen-presenting immune cell

Predicting the dose for repurposing nitazoxanide in COVID-19

People thinking they have had COVID-19 could increase transmission

OXGENE™ reports third consecutive year of 100% year on year revenue growth

Loss of smell may be related to neuroinvasive propensity of SARS-CoV-2

Uncovering immune cell reactions in COVID-19

New information on viral antigens could improve COVID-19 testing

Avacta Group plc forms COVID-19 antigen diagnostic collaboration with Adeptrix

ProteoGenix launches first Human Immune COVID-19 antibody library

GlobalData: Mass home testing for Covid-19 isn’t without its risks

C-Path receives EMA’s letter of support to facilitate the diagnoses of type 1 diabetes

Researchers receive ERC grant to speed up the diagnosis of autoimmune encephalitis

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest Life Science News